Mesoblast Limited (AU:MSB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited has received FDA approval for Ryoncil, making it the first mesenchymal stromal cell therapy approved in the U.S. for treating steroid-refractory acute graft versus host disease in children. This groundbreaking approval positions Ryoncil as a vital treatment option for a condition with limited alternatives and high mortality rates. With promising trial results, Mesoblast aims to extend Ryoncil’s application to other inflammatory conditions.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
